RGDK-lipopeptide for targeting genetic vaccines to antigen presenting cells.

Area of Science:

• Biotechnology
• Vaccinology
• Cell Biology

Background:

• Transfection into antigen-presenting cells (APCs) is crucial for DNA/mRNA vaccination but remains challenging.
• Previous liposome designs targeted the mannose receptor on dendritic cells (DCs).
• Integrin receptors on APCs represent an alternative target for cellular delivery.

Purpose of the Study:

• To develop integrin receptor-selective liposomes for DNA delivery to APCs.
• To evaluate the transfection efficiency of these liposomes in macrophages.
• To investigate the role of endosome-disrupting lipids in enhancing transfection.

Main Methods:

• Liposomes functionalized with RGDK-lipopeptide I were synthesized to target integrin receptors.
• pCMV-GFP plasmid DNA was encapsulated within the liposomes.
• Transfection efficiency was assessed in RAW 264.7 cells (mouse macrophages).
• The effect of incorporating histidinylated lipid II (endosome disruptor) on transfection was evaluated.

Main Results:

• RGDK-lipopeptide I liposomes successfully delivered pCMV-GFP DNA into RAW 264.7 cells.
• The presence of histidinylated lipid II significantly increased the transfection efficiency.
• This demonstrates the potential of integrin-targeted liposomes for gene delivery.

Conclusions:

• Integrin receptor-selective liposomes, particularly those incorporating endosome-disrupting lipids, are effective for DNA delivery to macrophages.
• These findings offer a promising strategy for developing advanced DNA vaccine carriers.
• This approach holds potential for future vaccines against infectious diseases and cancers.